Document is current
Any future updates will be listed below
-
Authors
Sarkar, Swarnavo https://orcid.org/0000-0002-1830-3099
Schechter, Clyde
Kurian, Allison W.
Caswell-Jin, Jennifer L.
Jayasekera, Jinani
Mandelblatt, Jeanne S.
-
Funding
Funding for this research was provided by:
National Cancer Institute (U01CA253911, U01CA253911, U01CA253911, U01CA253911, U01CA253911, U01CA253911)
National Institutes of Health Distinguished Scholars Program (MD000022)
- License Information
-
More Information
Article History
Received: 20 October 2024
Accepted: 15 March 2025
First Online: 26 March 2025
Competing interests
: Authors S.S., C.S., A.K., J.L.C., and J.J. declare no competing interests. Author J.S.M. is a co-inventor on a pending invention patent application un-related to this research. The patent application (PCT/US2022/028741) was filed by Georgetown University and is entitled “Use of RAGE inhibitors to Treat Cancer-Related Cognitive Decline” and is licensed to Cantex Pharmaceuticals. J.S.M. has waived her rights and will not receive any renumeration, consideration or revenue generated from this License or the patents and patent applications licensed thereunder.
